[go: up one dir, main page]

AR082645A1 - COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME - Google Patents

COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME

Info

Publication number
AR082645A1
AR082645A1 ARP110103104A AR082645A1 AR 082645 A1 AR082645 A1 AR 082645A1 AR P110103104 A ARP110103104 A AR P110103104A AR 082645 A1 AR082645 A1 AR 082645A1
Authority
AR
Argentina
Prior art keywords
ezatiostat
salt
per day
hydrochloride
grams
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Priority to ARP110103104 priority Critical patent/AR082645A1/en
Publication of AR082645A1 publication Critical patent/AR082645A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Regímenes de tratamiento específicos para tratar síndrome mielodisplásico.Reivindicación 1: El uso de una cantidad terapéuticamente eficaz de ezatiostat o una sal del mismo para la preparación de un medicamento oral para tratar un síndrome mielodisplásico, dicho ezatiostat o una sal del mismo es equivalente a hasta 2 gramos de ezatiostat clorhidrato por día durante al menos 2 semanas. Reivindicación 2: El uso de la reivindicación 1 donde el ezatiostat o una sal del mismo es ezatiostat clorhidrato. Reivindicación 3: El uso de la reivindicación 1, donde dicha cantidad terapéuticamente eficaz de ezatiostat clorhidrato es 2 gramos por día. Reivindicación 4: El uso de la reivindicación 3, donde el ezatiostat clorhidrato se administra en dos dosis separadas de 1 gramo por día. Reivindicación 5: El uso de la reivindicación 4, donde la segunda dosis se administra a un intervalo que va desde 6 hasta 14 horas después de la primera dosis. Reivindicación 10: Un método para tratar un síndrome mielodisplásico en un paciente cuyo método comprende administrar oralmente a dicho paciente una cantidad terapéuticamente eficaz de ezatiostat o una sal del mismo equivalente a hasta aproximadamente 2 gramos por día de ezatiostat clorhidrato durante al menos 2 semanas. Reivindicación 18: Una composición que comprende ezatiostat o una sal del mismo en una cantidad equivalente a hasta aproximadamente 2 gramos de ezatiostat clorhidrato por día durante al menos 2 semanas.Specific treatment regimens for treating myelodysplastic syndrome. Claim 1: The use of a therapeutically effective amount of ezatiostat or a salt thereof for the preparation of an oral medicament for treating a myelodysplastic syndrome, said ezatiostat or a salt thereof is equivalent to up to 2 grams of ezatiostat hydrochloride per day for at least 2 weeks. Claim 2: The use of claim 1 wherein the ezatiostat or a salt thereof is ezatiostat hydrochloride. Claim 3: The use of claim 1, wherein said therapeutically effective amount of ezatiostat hydrochloride is 2 grams per day. Claim 4: The use of claim 3, wherein the ezatiostat hydrochloride is administered in two separate doses of 1 gram per day. Claim 5: The use of claim 4, wherein the second dose is administered at an interval ranging from 6 to 14 hours after the first dose. Claim 10: A method of treating a myelodysplastic syndrome in a patient whose method comprises orally administering to said patient a therapeutically effective amount of ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride for at least 2 weeks. Claim 18: A composition comprising ezatiostat or a salt thereof in an amount equivalent to up to about 2 grams of ezatiostat hydrochloride per day for at least 2 weeks.

ARP110103104 2011-08-25 2011-08-25 COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME AR082645A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP110103104 AR082645A1 (en) 2011-08-25 2011-08-25 COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP110103104 AR082645A1 (en) 2011-08-25 2011-08-25 COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME

Publications (1)

Publication Number Publication Date
AR082645A1 true AR082645A1 (en) 2012-12-19

Family

ID=47562094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103104 AR082645A1 (en) 2011-08-25 2011-08-25 COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME

Country Status (1)

Country Link
AR (1) AR082645A1 (en)

Similar Documents

Publication Publication Date Title
RU2013121788A (en) HIV REPLICATION INHIBITORS
BR112015029491A2 (en) imidazopyrrolidinone derivatives and their use in the treatment of disease
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
AR090885A1 (en) USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
BR112015029512A2 (en) pyrazolopyrrolidine derivatives and their use in the treatment of diseases
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
UA107578C2 (en) COMBINED DIABETES THERAPY
EA201491285A1 (en) IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID
EA201590166A1 (en) COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
BR112015010396A2 (en) combination therapy
EA201490378A1 (en) TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
ES2570401T3 (en) Methods of treatment using single doses of oritavancin
HRP20192189T1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
AR088204A1 (en) MEDICINES FOR THE TREATMENT OF ALLERGY RHINITIS THAT INCLUDE A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST
AR091724A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION
BR112012020377A2 (en) use of one or more selected from the group consisting of a compound of formula (i), a racemic-diastereomeric mixture and an optical isomer of said compound, and a pharmaceutically acceptable salt and prodrug thereof, method, pharmaceutical composition and treatment kit cachexia and commercial packaging
BR112014004339A2 (en) oral suspension
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
AR082645A1 (en) COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME
EP2593460A4 (en) 7,9-NITROGEN-RADIKAL-4-OXO-4H-PYRIDO- [L, 2-A-] PYRIMIDIN-2-CARBOXYLIC ACID BENZYLAMIDE VIROSTATIKA
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.

Legal Events

Date Code Title Description
FB Suspension of granting procedure